Scinai Immunotherapeutics
SCNI
16 hedge funds and large institutions have $1.08M invested in Scinai Immunotherapeutics in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
73% more capital invested
Capital invested by funds: $623K → $1.08M (+$454K)
60% more funds holding
Funds holding: 10 → 16 (+6)
0.33% more ownership
Funds ownership: 1.2% → 1.54% (+0.33%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$140K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$127K |
| 3 |
Goldman Sachs
New York
|
+$118K |
| 4 |
VF
Virtu Financial
New York
|
+$78.6K |
| 5 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
+$52.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$140K |
| 2 |
Morgan Stanley
New York
|
-$82.9K |
| 3 |
Two Sigma Investments
New York
|
-$76K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$4.37K |
SCNI Hedge Fund Activity: Q1 2021 in Review
16 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2021, worth a combined $1.08M — up 73% from $623K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SCNI positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $140K. The largest seller was ARK Investment Management, cutting an estimated $140K.
- 16 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2021, up from 10 in Q4 2020.
- Funds reported $1.08M of Scinai Immunotherapeutics stock for Q1 2021, up 73% quarter-over-quarter.
- 7 funds opened new Scinai Immunotherapeutics positions in Q1 2021 and 1 closed out, a net change of +6 holders.
- The largest Scinai Immunotherapeutics buyer in Q1 2021 was HRT Financial, an estimated $140K added.
- The largest Scinai Immunotherapeutics seller in Q1 2021 was ARK Investment Management, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2021.